Johnson & Johnson Innovation – JJDC — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Georgiamunegeorgiamune.com inJul 2026SEC filingmedium confidence

Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.

BiotechDeep TechHealthtechGaithersburg, US

Samir N. Khleif(Founder & CEO)inRamy Ibrahim(Chief Medical and Strategy Officer)inMikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)

BoardSean Parker(Director)Elena Viboch(Director)in

Board seatNancy Ondovik· per SEC Form D · $131.9M raise · filed Aug 2026

Co-investorsCatalio Capital Management, LP General Catalyst HAWKTAIL Lauder Partners Prevail Venture Capital Alexandria +3 more

SonoTherasonothera.com in 𝕏Jun 2026

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US

Kenneth Greenberg(Co-Founder, President & CEO)in

Co-investorsVida Ventures Leaps by Bayer ARCH Venture Partners Foothill Ventures Illumina Ventures Medical Excellence Capital +8 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.